Stingray Therapeutics
Stingray Therapeutics is a clinical stage biotech company focused on developing next-generation immune therapies to combat cancer. Their revolutionary approach enables the full immune system to fight back against cancer, targeting innate immunity checkpoint ENPP1 to enhance immune response and reduce tumor resistance.
Industries
Nr. of Employees
small (1-50)
Stingray Therapeutics
TMCxi – Texas Medical Center, 2450 Holcombe Blvd, Suite 1.305, Houston, TX 77021
Patents
Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof
US-12152015-B2
View DetailsInhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof
US-11591313-B2
View DetailsSubstituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics
US-11142524-B2
View DetailsSubstituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics
US-10689376-B2
View Details
Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof
US-12152015-B2
View DetailsInhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof
US-11591313-B2
View DetailsSubstituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics
US-11142524-B2
View DetailsSubstituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics
US-10689376-B2
View DetailsProducts
Clinical-stage ENPP1-targeting immunotherapy candidate(s)
Therapeutic candidates developed to inhibit ENPP1 and reactivate innate immune signaling (cGAS–STING pathway) in tumors; development includes small-molecule inhibitor programs and clinical-stage immunotherapy efforts.
Clinical-stage ENPP1-targeting immunotherapy candidate(s)
Therapeutic candidates developed to inhibit ENPP1 and reactivate innate immune signaling (cGAS–STING pathway) in tumors; development includes small-molecule inhibitor programs and clinical-stage immunotherapy efforts.
Services
Partnership-based preclinical development and testing of oncology therapeutic candidates in collaboration with external research institutes.
Partnership-based preclinical development and testing of oncology therapeutic candidates in collaboration with external research institutes.
Expertise Areas
- Immunotherapy development
- Cancer drug discovery (ENPP1-focused)
- Preclinical and translational research
- Clinical trial operations and management
Key Technologies
- ENPP1 inhibition
- cGAS–STING pathway assays
- Small-molecule medicinal chemistry
- Oral small-molecule candidate development
News & Updates
Various news articles and updates about Stingray Therapeutics, including breakthroughs in immune-boosting therapies, funding awards, and founder stories.
Details about the company's scientific approach targeting ENPP1, the role of the cGAS-STING pathway, and their research presentations.
Overview of the company's mission, recent achievements, and contact information.
Contact information for the company's offices in Houston and Dallas, and a contact form.
Profiles of the company's leadership team, including CEO Jonathan Northrup and other biotech specialists.
An article discussing Stingray's innovative approach to cancer immunotherapy.
Various news articles and updates about Stingray Therapeutics, including breakthroughs in immune-boosting therapies, funding awards, and founder stories.
Details about the company's scientific approach targeting ENPP1, the role of the cGAS-STING pathway, and their research presentations.
Overview of the company's mission, recent achievements, and contact information.
Contact information for the company's offices in Houston and Dallas, and a contact form.
Profiles of the company's leadership team, including CEO Jonathan Northrup and other biotech specialists.
An article discussing Stingray's innovative approach to cancer immunotherapy.